Karolina Anderson, MD
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1417319369
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 449 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,388, more than ten times the $19 reported in 2019.
Across 449 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Xeris Pharmaceuticals, Inc.$673
- Insulet Corporation$499
- Sanofi-aventis U.S. LLC$498
- Cequr Corporation$478
- plus $5K from 35 others
What the payments were for
- Food & beverage$9,302100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $1,168 |
| Lilly USA, LLC | 53 | $1,071 |
| Xeris Pharmaceuticals, Inc. | 31 | $673 |
| Insulet Corporation | 27 | $499 |
| Sanofi-aventis U.S. LLC | 25 | $498 |
| Cequr Corporation | 3 | $478 |
| Amgen | 25 | $475 |
| Bayer | 17 | $352 |
| Averitas Pharma Inc. | 14 | $329 |
| BETA Bionics, Inc. | 11 | $279 |
| Sequel Med Tech, LLC | 9 | $278 |
| Radius Health, Inc. | 13 | $258 |
| Dexcom, Inc. | 24 | $251 |
| Corcept Therapeutics | 10 | $232 |
| Medtronic | 7 | $222 |
| Mannkind Corporation | 8 | $206 |
| AbbVie | 10 | $179 |
| AstraZeneca(2 entities) | 9 | $172 |
| Abbott | 23 | $151 |
| Chiesi USA, Inc. | 7 | $150 |
| Boehringer Ingelheim | 7 | $136 |
| Kyowa Kirin, Inc. | 7 | $133 |
| Tandem Diabetes Care, Inc. | 4 | $121 |
| IBSA Pharma Inc. | 6 | $100 |
| Pfizer | 4 | $97 |
| Ascensia Diabetes Care US Inc. | 4 | $91 |
| Antares Pharma, Inc. | 5 | $91 |
| Ultragenyx Pharmaceutical Inc. | 3 | $84 |
| Novartis | 4 | $82 |
| Neurocrine Biosciences, Inc. | 3 | $80 |
| Ascendis Pharma Endocrinology Inc | 4 | $76 |
| Amphastar Pharmaceuticals, Inc. | 3 | $62 |
| Amneal Pharmaceuticals LLC | 3 | $60 |
| Rhythm Pharmaceuticals, Inc. | 2 | $41 |
| Recordati_rare_diseases_inc. | 2 | $40 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Acella Pharmaceuticals, LLC | 1 | $23 |
| Tolmar, Inc. | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Nevro Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$439
- RYBELSUS$104
How this compares
$9,335 in reported general payments places this provider in the 65th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 306 | $350,816 |
| MounjaroTirzepatide | 229 | $263,596 |
| TymlosAbaloparatide | 56 | $254,214 |
| Tresiba Flextouch U-200Insulin Degludec | 87 | $90,209 |
| JardianceEmpagliflozin | 62 | $73,334 |
| TrulicityDulaglutide | 33 | $61,788 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 31 | $57,219 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 39 | $39,034 |
| FarxigaDapagliflozin Propanediol | 27 | $29,820 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $18,716 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $18,409 |
| KerendiaFinerenone | 16 | $17,824 |
| Novolog FlexpenInsulin Aspart | 28 | $15,298 |
| NovologInsulin Aspart | 40 | $13,087 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $13,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,168 | $363,903346 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $1,071 | $326,804281 claims |
| Radius Health, Inc.Tymlos | $258 | $254,21456 claims |
| Boehringer IngelheimJardiance | $136 | $73,33462 claims |
| AstraZenecaFarxiga | $172 | $29,82027 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $498 | $18,40915 claims |
| BayerKerendia | $352 | $17,82416 claims |
| AbbVieSynthroid | $179 | $5,67279 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $60 | $3,925262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Nashville
- Craig WierumNashville$1.3M
- Terri JerkinsNashville$567K
- Michael CarlsonNashville$381K
- Kathryn DahirNashville$225K
- Rodney SnowNashville$181K
- Annis MarneyNashville$26K
- Emily NeelyNashville$21K
- Amanda DanielNashville$20K
- Juliana MatthewsNashville$15K
- Christopher BowmanNashville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.